Colorectal Cancer (Third-Line Advanced/Metastatic) | Decision Base | US | 2015

How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market?

Patients with advanced/metastatic colorectal cancer (mCRC) typically receive chemotherapy (with or without biologics) as treatment, which increases overall survival (OS) but can also lead to severe toxicities. Patients in the third-line setting have limited therapeutic options and typically have a reduced quality of life; therefore, physicians must carefully balance any efficacy benefit associated with a therapy with its toxicity profile. The launch of regorafenib (Bayer HealthCare’s Stivarga) and the anticipated launch of TAS-102 (Taiho Pharmaceutical’s Lonsurf) in the United States and Europe will increase the number of viable treatment options for these patients, and those who are RAS wild-type can also receive an EGFR inhibitor (such as cetuximab [Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux] and panitumumab [Amgen/Takeda Pharmaceutical’s Vectibix]) if they have not received one previously. However, given that the efficacy associated with these therapies is limited, significant opportunity remains for emerging therapies in development for this patient population.

Login to access report